A case-control study of apoA5 −1131T→C polymorphism that examines the role of triglyceride levels in diabetic nephropathy

Baroukh, 2004, Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice, Arteriosclerosis Thrombosis & Vascular Biology, 24, 1297, 10.1161/01.ATV.0000130463.68272.1d Baum, 2003, APOA5−1131T>C polymorphism is associated with triglyceride levels in Chinese men, Clinical Genetics, 63, 377, 10.1034/j.1399-0004.2003.00063.x Bi, 2004, A single nucleotide polymorphism −1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese, Molecular Genetics & Metabolism, 83, 280, 10.1016/j.ymgme.2004.06.017 Bonnet, 2000, Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies, Diabetes Metabolism, 26, 254 Chavers, 1994, Relationship between retinal and glomerular lesions in IDDM patients, Diabetes, 43, 441, 10.2337/diabetes.43.3.441 Colhoun, 2001, Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes, Diabetologia, 44, S46, 10.1007/PL00002939 Coonrod, 1993, Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study, Diabetes Care, 16, 1376, 10.2337/diacare.16.10.1376 Cooper, 1998, Pathogenesis, prevention, and treatment of diabetic nephropathy, Lancet, 352, 213, 10.1016/S0140-6736(98)01346-4 Endo, 2002, Association found between the promoter region polymorphism in the apolipoprotein A–V gene and the serum triglyceride level in Japanese schoolchildren, Human Genetics, 111, 570, 10.1007/s00439-002-0825-0 Fagot-Campagna, 1998, Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: The Strong Heart Study, Diabetologia, 41, 1002, 10.1007/s001250051023 Fruchart-Najib, 2004, Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5, Biochemical & Biophysical Research Communications, 319, 397, 10.1016/j.bbrc.2004.05.003 Giorgino, 2004, Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: The EURODIAB Prospective Complications Study, Diabetologia, 47, 1020, 10.1007/s00125-004-1413-8 Hadjadj, 2004, Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes, Diabetes Metabolism, 30, 43, 10.1016/S1262-3636(07)70088-5 Iseki, 2005, Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort, Clinical & Experimental Nephrology, 9, 46, 10.1007/s10157-004-0332-9 Jenkins, 2003, Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy, Kidney International, 64, 817, 10.1046/j.1523-1755.2003.00164.x Kim, 2004, An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea, Diabetes Research & Clinical Practice, 66, S169, 10.1016/j.diabres.2004.07.011 Martin, 2003, Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges, Biochimica et Biophysica Acta, 1637, 217, 10.1016/S0925-4439(03)00033-4 Masana, 2003, The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects, Clinical Chemistry & Laboratory Medicine, 41, 517, 10.1515/CCLM.2003.078 Merkel, 2005, Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase, Journal of Biological Chemistry, 280, 21553, 10.1074/jbc.M411412200 Muntner, 2000, Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study, Kidney International, 58, 293, 10.1046/j.1523-1755.2000.00165.x Nishida, 1999, Effect of lipoproteins on mesangial cell proliferation, Kidney International, S51, 10.1046/j.1523-1755.1999.07113.x O'Brien, 2005, The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins, Clinical Chemistry, 51, 351, 10.1373/clinchem.2004.040824 Orchard, 2001, Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study, Diabetes Care, 24, 1053, 10.2337/diacare.24.6.1053 Pennacchio, 2001, An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing, Science, 294, 169, 10.1126/science.1064852 Pirart, 1977, Diabete Metab, 3, 97 Ravid, 1998, Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia, Archives of Internal Medicine, 158, 998, 10.1001/archinte.158.9.998 Rogus, 2002, Genetic studies of late diabetic complications: The overlooked importance of diabetes duration before complication onset, Diabetes, 51, 1655, 10.2337/diabetes.51.6.1655 Sambrook, 1989, E3 Seaquist, 1989, Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy, New England Journal of Medicine, 320, 1161, 10.1056/NEJM198905043201801 van der Vliet, 2002, Adenoviral overexpression of apolipoprotein A–V reduces serum levels of triglycerides and cholesterol in mice, Biochemical & Biophysical Research Communications, 295, 1156, 10.1016/S0006-291X(02)00808-2 Wang, 2003, Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes, Diabetes Care, 26, 2410, 10.2337/diacare.26.8.2410